Literature DB >> 8640982

Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo.

T Münzel1, E Bassenge.   

Abstract

BACKGROUND: Rebound myocardial ischemia develops in patients with unstable or stable angina pectoris after sudden cessation of nitroglycerin therapy. Long-term nitroglycerin infusion is associated with increases in plasma renin activity and catecholamine release rates, both of which may lead to excess angiotensin II and alpha-adrenergic-mediated vasoconstriction, particularly on withdrawal of nitroglycerin. METHODS AND
RESULTS: Chronically instrumented dogs were treated for 5 days with nitroglycerin (1.5 micrograms.kg-1.min-1 i.v.) alone or in combination with the angiotensin-converting enzyme (ACE) inhibitor enalapril (0.1 mg/kg two times daily or 1 mg/kg). With long-term nitroglycerin therapy, the left anterior circumflex artery was maximally dilated 4 hours after the start of nitroglycerin infusion (9.5 +/- 0.6%) and returned to baseline levels within the third day of treatment (baseline, 2.52 +/- 0.07 mm; day 3, 2.55 +/- 0.07 mm; P = NS), indicating a complete loss of nitroglycerin-induced coronary vasodilatation. Nitroglycerin infusion also was accompanied by a transient increase in plasma renin activity. Sudden withdrawal of nitroglycerin infusion caused a progressive constriction of the left anterior circumflex artery, which peaked 4 hours after nitroglycerin infusion cessation (-7.8 +/- 0.2%). This occurred in the absence of elevated plasma renin activity. Concomitant treatment with high-dose enalapril (1 mg.kg-1.d-1) markedly reduced the degree of tolerance and prevented the rebound constriction on cessation of nitroglycerin therapy.
CONCLUSIONS: Long-term ACE inhibition with high-dose enalapril reduces nitroglycerin tolerance and prevents rebound vasoconstriction in coronary arteries. These phenomena were not associated with an activated circulating renin-angiotensin system. This observation suggests that during long-term nitroglycerin treatment, intrinsic abnormalities of the vascular smooth muscle may have developed that are suppressed by concomitant ACE inhibitor therapy. The present study also favors a combination of nitroglycerin and ACE inhibitors to maintain nitrate sensitivity of the vasculature during long-term nitroglycerin treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640982     DOI: 10.1161/01.cir.93.11.2052

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Crosstalk between endothelin and nitric oxide in the control of vascular tone.

Authors:  M Lavallée; M Takamura; R Parent; E Thorin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state.

Authors:  E Bassenge; B Fink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

3.  Characteristics of attenuated endothelium-dependent relaxation seen in rabbit intrapulmonary vein following chronic nitroglycerine administration.

Authors:  Nobuyoshi Kusama; Junko Kajikuri; Yoshimasa Watanabe; Yoshikatsu Suzuki; Hirotada Katsuya; Takeo Itoh
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Dietary supplement with vitamin C prevents nitrate tolerance.

Authors:  E Bassenge; N Fink; M Skatchkov; B Fink
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 5.  Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.

Authors:  Katherine E Fayers; Michael H Cummings; Kenneth M Shaw; David W Laight
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 6.  Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.

Authors:  Matthias Oelze; Swenja Schuhmacher; Andreas Daiber
Journal:  Exp Diabetes Res       Date:  2010-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.